Conference Proceedings
609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
B Tran, L Horvath, T Dorff, M Rettig, MP Lolkema, J-P Machiels, S Rottey, K Autio, R Greil, N Adra, C Lemech, M Minocha, F-C Cheng, H Kouros-Mehr, K Fizazi
Annals of Oncology | Elsevier BV | Published : 2020